nach oben

Erschienen in:

01.10.2012 | Research

Prognostic Value of TOP2A Gene Amplification and Chromosome 17 Polysomy in Early Breast Cancer

verfasst von: Anna Żaczek, Aleksandra Markiewicz, Anna Supernat, Natalia Bednarz-Knoll, Burkhardt Brandt, Barbara Seroczyńska, Jarosław Skokowski, Jolanta Szade, Piotr Czapiewski, Wojciech Biernat, Marzena Wełnicka-Jaśkiewicz, Jacek Jassem

Erschienen in: Pathology & Oncology Research | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to analyze the occurrence of TOP2A gene amplification and chromosome 17 polysomy in patients with early breast cancer and to correlate the status of these alterations with the prognostic significance expressed as patients’ clinical features and survival. Such concurrent analyses of TOP2A gene status and chromosome 17 polysomy have not been performed before. Study group included 149 consecutive stage I-III patients administered standard multimodality treatment. TOP2A abnormalities were examined by standard fluorescence in situ hybridization (FISH) and developed by our group quantitative real-time PCR (qPCR). TOP2A amplification and deletion assessed by FISH were found in 23% and 7% of the tumours, respectively, and by qPCR in 31% and 11% of the tumours, respectively. Chromosome 17 polysomy was detected in 40% of the cases. TOP2A amplification (by qPCR) correlated with shorter disease-free survival (p = 0.03) and overall survival (p = 0.047), and the prognostic value of TOP2A was confirmed in the multivariate analysis (HR = 3.22, 95% CI 1.09–9.56, p = 0.03). TOP2A gene amplification, but not chromosome 17 polysomy, carries negative prognostic information in early breast cancer. Given the aforementioned results, qPCR might serve as a prognostic tool in determining the patient’s prognosis.

Lehmann U, Glöckner S, Kleeberger W, Feist H, Rv W, Kreipe H (2000) Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction. Am J Pathol 156(6):1855–1864PubMedCrossRef

Mano MS, Rosa DD, Azambuja ED, Ismael GFV, Durbecq V (2007) The 17q12-q21 amplicon: Her2 and topoisomerase-IIa and their importance to the biology of solid tumours. Cancer Treat Rev 33:64–77PubMedCrossRef

Park K, Kim J, Lim S, Han S (2003) Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer 39(5):631–634. doi:S0959804902007451 PubMedCrossRef

Järvinen TAH, Liu ET (2003) HER-2/neu and topoisomerase IIα in breast cancer. Breast Cancer Res Treat 78:299–311PubMedCrossRef

Durbecq V, Paesmans M, Cardoso F, Desmedt C, Di Leo A, Chan S, Friedrichs K, Pinter T, Van Belle S, Murray E, Bodrogi I, Walpole E, Lesperance B, Korec S, Crown J, Simmonds P, Perren TJ, Leroy JY, Rouas G, Sotiriou C, Piccart M, Larsimont D (2004) Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther 3(10):1207–1214. doi:3/10/1207 PubMed

O’Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, Andrulis IL, Pritchard KI (2009) Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 101(9):644–650. doi:djp067 PubMedCrossRef

Arriola E, Maria S, Rodriguez-Pinilla LMBK, Jones RL, James M, Savage K, Smith IE, Dowsett M, Reis-Filho JS (2007) Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat 106:181–189PubMedCrossRef

Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsdottir K, Olsen KE, Mouridsen H, Ejlertsen B (2005) Retrospective analysis of Topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23(20):7483–7490PubMedCrossRef

Nielsen KV, Ejlertsen B, Moller S, Jorgensen JT, Knoop A, Knudsen H, Mouridsen HT (2008) The value of TOP2A gene copy number variation as a biomarker in breast cancer: update of DBCG trial 89D. Acta Oncol 47(4):725–734. doi:791851530 PubMedCrossRef

10.

Park K, Han S, Gwak GH, Kim HJ, Kim J, Kim KM (2006) Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer. Breast Cancer Res Treat 98(3):337–342. doi:10.1007/s10549-006-9170-7 PubMedCrossRef

11.

Shackney SE, Singh SG, Yakulis R, Smith CA, Pollice AA, Petruolo S, Waggoner A, Hartsock RJ (1995) Aneuploidy in breast cancer: a fluorescence in situ hybridization study. Cytometry 22(4):282–291. doi:10.1002/cyto.990220404 PubMedCrossRef

12.

Staaf J, Jonsson G, Ringner M, Vallon-Christersson J, Grabau D, Arason A, Gunnarsson H, Agnarsson BA, Malmstrom PO, Johannsson OT, Loman N, Barkardottir RB, Borg A (2010) High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Res 12(3):R25. doi:bcr2568 PubMedCrossRef

13.

Gunn S, Yeh IT, Lytvak I, Tirtorahardjo B, Dzidic N, Zadeh S, Kim J, McCaskill C, Lim L, Gorre M, Mohammed M (2010) Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity. BMC Cancer 10:396. doi:1471-2407-10-396 PubMedCrossRef

14.

Moelans CB, de Weger RA, van Diest PJ (2009) Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Res Treat 120(1):1–7. doi:10.1007/s10549-009-0539-2 PubMedCrossRef

15.

Reinholz MM, Bruzek AK, Visscher DW, Lingle WL, Schroeder MJ, Perez EA, Jenkins RB (2009) Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. Lancet Oncol 10(3):267–277. doi:S1470-2045(09)70063-4 PubMedCrossRef

16.

Krishnamurti U, Hammers JL, Atem FD, Storto PD, Silverman JF (2009) Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma. Mod Pathol 22(8):1044–1048. doi:modpathol200961 PubMedCrossRef

17.

Watters AD, Going JJ, Cooke TG, Bartlett JM (2003) Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat 77(2):109–114PubMedCrossRef

18.

Vanden Bempt I, Van Loo P, Drijkoningen M, Neven P, Smeets A, Christiaens MR, Paridaens R, De Wolf-Peeters C (2008) Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol 26(30):4869–4874. doi:JCO.2007.13.4296 PubMedCrossRef

19.

Torrisi R, Rotmensz N, Bagnardi V, Viale G, Curto BD, Dell’orto P, Veronesi P, Luini A, D’Alessandro C, Cardillo A, Goldhirsch A, Colleoni M (2007) HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17. Eur J Cancer 43(16):2339–2344. doi:S0959-8049(07)00560-6 PubMedCrossRef

20.

Järvinen T, Tanner M, Rantanen V, Bärlund M, Borg Å, Grènman S (2000) Amplification and deletion of topoisomerase IIa associate with ErbB-2 amplification and affect sensitivity to topoisomerase II Inhibitor doxorubicin in breast cancer. Am J Pathol 156:839–847PubMedCrossRef

21.

Zaczek A, Markiewicz A, Jaskiewicz J, Pienkowski T, Rhone P, Jassem J, Welnicka-Jaskiewicz M (2010) Clinical evaluation of developed PCR-based method with hydrolysis probes for TOP2A copy number evaluation in breast cancer samples. Clin Biochem 43(10–11):891–898. doi:S0009-9120(10)00193-1 PubMedCrossRef

22.

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93(4):387–391. doi:6602678 PubMedCrossRef

23.

Romero A, Martín M, Cheang MC, López García-Asenjo JA, Oliva B, He X, de la Hoya M, García Sáenz J, Arroyo Fernández M, Díaz Rubio E, Perou CM, Llopis TC (2011) Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization. Am J Pathol 178(4):1453–1460. doi:S0002-9440(11)00042-3 PubMedCrossRef

24.

Hicks DG, Yoder BJ, Pettay J, Swain E, Tarr S, Hartke M, Skacel M, Crowe JP, Budd T, Tubbs RR (2004) The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: A fluorescence in situ hybridization study. Hum Pathol 36(4):348–356CrossRef

25.

Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ (2002) HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 8(5):1107–1116PubMed

26.

Konecny GE, Pauletti G, Untch M, Wang HJ, Mobus V, Kuhn W, Thomssen C, Harbeck N, Wang L, Apple S, Janicke F, Slamon DJ (2010) Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer. Breast Cancer Res Treat 120(2):481–489. doi:10.1007/s10549-010-0744-z PubMedCrossRef

27.

Slamon DJ, Press MF (2009) Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers. J Natl Cancer Inst 101(9):615–618. doi:djp092 PubMedCrossRef

28.

Herrington CS, Leek RD, McGee JO (1995) Correlation of numerical chromosome 11 and 17 imbalance with metastasis of primary breast cancer to lymph nodes. J Pathol 176(4):353–359. doi:10.1002/path.1711760406 PubMedCrossRef

29.

Ichikawa D, Hashimoto N, Hoshima M, Yamaguchi T, Sawai K, Nakamura Y, Takahashi T, Abe T, Inazawa J (1996) Analysis of numerical aberrations of specific chromosomes by fluorescent in situ hybridization as a diagnostic tool in breast cancer. Cancer 77(10):2064–2069. doi:10.1002/(SICI)1097-0142(19960515)77:10<2064::AID-CNCR15>3.0.CO;2-TPubMedCrossRef

30.

McManus DT, Patterson AH, Maxwell P, Hamilton PW, Anderson NH, Caughley LM, Toner PG (1999) Interphase cytogenetics of chromosomes 11 and 17 in fine needle aspirates of breast cancer. Hum Pathol 30(2):137–144PubMedCrossRef

31.

Tsukamoto F, Miyoshi Y, Egawa C, Kasugai T, Takami S, Inazawa J, Noguchi S (2001) Clinicopathologic analysis of breast carcinoma with chromosomal aneusomy detected by fluorescence in situ hybridization. Cancer 93(2):165–170PubMedCrossRef

32.

Fehm T, Morrison L, Saboorian H, Hynan L, Tucker T, Uhr J (2002) Patterns of aneusomy for three chromosomes in individual cells from breast cancer tumors. Breast Cancer Res Treat 75(3):227–239PubMedCrossRef

33.

Nakopoulou L, Giannopoulou I, Trafalis D, Gakiopoulou H, Keramopoulos A, Davaris P (2002) Evaluation of numeric alterations of chromosomes 1 and 17 by in situ hybridization in invasive breast carcinoma with clinicopathologic parameters. Appl Immunohistochem Mol Morphol 10(1):20–28PubMedCrossRef

34.

Wang S, Hossein Saboorian M, Frenkel EP, Haley BB, Siddiqui MT, Gokaslan S, Hynan L, Ashfaq R (2002) Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol 15(2):137–145. doi:10.1038/modpathol.3880505 PubMedCrossRef

35.

Ma Y, Lespagnard L, Durbecq V, Paesmans M, Desmedt C, Gomez-Galdon M, Veys I, Cardoso F, Sotiriou C, Di Leo A, Piccart MJ, Larsimont D (2005) Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res 11(12):4393–4399. doi:11/12/4393 PubMedCrossRef

36.

Merola R, Mottolese M, Orlandi G, Vico E, Cognetti F, Sperduti I, Fabi A, Vitelli G, Cianciulli AM (2006) Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis. Eur J Cancer 42(10):1501–1506. doi:S0959-8049(06)00319-4 PubMedCrossRef

37.

Dowsett M, Hanna WM, Kockx M, Penault-Llorca F, Ruschoff J, Gutjahr T, Habben K, van de Vijver MJ (2007) Standardization of HER2 testing: results of an international proficiency-testing ring study. Mod Pathol 20(5):584–591. doi:3800774 PubMedCrossRef

38.

Marchio C, Lambros MB, Gugliotta P, Di Cantogno LV, Botta C, Pasini B, Tan DS, Mackay A, Fenwick K, Tamber N, Bussolati G, Ashworth A, Reis-Filho JS, Sapino A (2009) Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol 219(1):16–24. doi:10.1002/path.2574 PubMedCrossRef

39.

Beser AR, Tuzlali S, Guzey D, Dolek Guler S, Hacihanefioglu S, Dalay N (2007) HER-2, TOP2A and chromosome 17 alterations in breast cancer. Pathol Oncol Res 13(3):180–185. doi:PAOR.2007.13.3.0180 PubMedCrossRef

40.

Järvinen TA, Tanner M, Bärlund M, Borg A, Isola J (1999) Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 26(2):142–150. doi:10.1002/(SICI)1098-2264(199910)26:2<142::AID-GCC6>3.0.CO;2-BPubMedCrossRef

41.

Brase JC, Schmidt M, Fischbach T, Sultmann H, Bojar H, Koelbl H, Hellwig B, Rahnenfuhrer J, Hengstler JG, Gehrmann MC (2010) ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin Cancer Res 16(8):2391–2401. doi:1078-0432.CCR-09-2471 PubMedCrossRef

42.

Bartlett JM, Munro AF, Dunn JA, McConkey C, Jordan S, Twelves CJ, Cameron DA, Thomas J, Campbell FM, Rea DW, Provenzano E, Caldas C, Pharoah P, Hiller L, Earl H, Poole CJ (2010) Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol 11(3):266–274. doi:S1470-2045(10)70006-1 PubMedCrossRef

43.

Downey L, Livingston RB, Koehler M, Arbushites M, Williams L, Santiago A, Guzman R, Villalobos I, Di Leo A, Press MF (2010) Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. Clin Cancer Res 16(4):1281–1288. doi:1078-0432.CCR-09-1643 PubMedCrossRef

44.

Bartlett JMS, Munro A, Cameron DA, Thomas J, Prescott R, Twelves CJ (2008) Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol 28(31)

45.

Glynn RW, Miller N, Whelan MC, Kerin MJ (2010) Topoisomerase 2 alpha and the case for individualized breast cancer therapy. Ann Surg Oncol 17(5):1392–1397. doi:10.1245/s10434-009-0855-0 PubMedCrossRef

46.

Bednarz N, Eltze E, Semjonow A, Rink M, Andreas A, Mulder L, Hannemann J, Fisch M, Pantel K, Weier HU, Bielawski KP, Brandt B (2010) BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood. Clin Cancer Res 16(13):3340–3348. doi:1078-0432.CCR-10-0150 PubMedCrossRef

47.

Salido M, Tusquets I, Corominas JM, Suarez M, Espinet B, Corzo C, Bellet M, Fabregat X, Serrano S, Sole F (2005) Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. Breast Cancer Res 7(2):R267–273. doi:bcr996 PubMedCrossRef

Titel: Prognostic Value of TOP2A Gene Amplification and Chromosome 17 Polysomy in Early Breast Cancer
verfasst von: Anna Żaczek
Aleksandra Markiewicz
Anna Supernat
Natalia Bednarz-Knoll
Burkhardt Brandt
Barbara Seroczyńska
Jarosław Skokowski
Jolanta Szade
Piotr Czapiewski
Wojciech Biernat
Marzena Wełnicka-Jaśkiewicz
Jacek Jassem
Publikationsdatum: 01.10.2012
Verlag: Springer Netherlands
Erschienen in: Pathology & Oncology Research / Ausgabe 4/2012
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-012-9518-8

Springer Medizin

Prognostic Value of TOP2A Gene Amplification and Chromosome 17 Polysomy in Early Breast Cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

Primary Esophageal Small Cell Carcinoma with Brain Metastasis and with CD56, KIT, and PDGFRA Expressions

Second Allogeneic Transplantation for Relapsed Acute Leukemia after Initial Allogeneic Hematopoietic Stem Cell Transplantation

Tissue-Specific Homing of Immune Cells in Malignant Skin Tumors

Increased Expression of FAT10 is Correlated with Progression and Prognosis of Human Glioma

The Expression of High Mobility Group Box 1 is Associated with Lymph Node Metastasis and Poor Prognosis in Esophageal Squamous Cell Carcinoma

CT Scan is not Everything in the Evaluation of a Patient with Gastrointestinal Tumors (GIST) Under Imatinib Therapy

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie